<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma - Anderson, DE - 2015 | Cochrane Library</title> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma - Anderson, DE - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011397.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma - Anderson, DE - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011397.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011397.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma" name="citation_title"/> <meta content="Debbie E Anderson" name="citation_author"/> <meta content="University of Strathclyde" name="citation_author_institution"/> <meta content="debbie.anderson@strath.ac.uk" name="citation_author_email"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Anne C Boyter" name="citation_author"/> <meta content="University of Strathclyde" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD011397.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/08/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011397.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011397.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011397.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenal Cortex Hormones [*administration &amp; dosage, adverse effects]; Anti‐Asthmatic Agents [*administration &amp; dosage, adverse effects]; Asthma [*drug therapy]; Disease Progression; Drug Therapy, Combination [methods]; Muscarinic Antagonists [*administration &amp; dosage, adverse effects]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011397.pub2&amp;doi=10.1002/14651858.CD011397.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011397\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011397\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011397.pub2",title:"Long\\u2010acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma",firstPublishedDate:"Aug 24, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011397.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011397.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011397.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011397.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011397.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011397.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011397.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011397.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011397.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011397.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1453 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011397.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-sec-0089"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/appendices#CD011397-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/table_n/CD011397StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/table_n/CD011397StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information#CD011397-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Debbie E Anderson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information#CD011397-cr-0003">Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information#CD011397-cr-0004">Anne C Boyter</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information/en#CD011397-sec-0109">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 August 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011397.pub2">https://doi.org/10.1002/14651858.CD011397.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011397-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011397-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011397-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011397-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011397-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011397-abs-0001" lang="en"> <section id="CD011397-sec-0001"> <h3 class="title" id="CD011397-sec-0001">Background</h3> <p>Despite the availability of several evidence‐based therapies and non‐pharmacological strategies to improve control of symptoms and prevent exacerbations of asthma, patients with asthma continue to be at risk for mortality and morbidity. </p> <p>Previous trials have demonstrated the potentially beneficial effects of the long‐acting muscarinic antagonist (LAMA) tiotropium on lung function in patients with asthma; however, a definitive conclusion on the benefit of LAMA in asthma is lacking, as is information on where in the current step‐wise management strategy they would be most beneficial. </p> </section> <section id="CD011397-sec-0002"> <h3 class="title" id="CD011397-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of a LAMA added to any dose of an inhaled corticosteroid (ICS) compared with the same dose of ICS alone for adults whose asthma is not well controlled. </p> </section> <section id="CD011397-sec-0003"> <h3 class="title" id="CD011397-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register (CAGR) from inception to April 2015, and we imposed no restriction on language of publication. We also searched clinicaltrials.gov, the World Health Organization (WHO) trials portal and drug company registries to identify unpublished studies. </p> </section> <section id="CD011397-sec-0004"> <h3 class="title" id="CD011397-sec-0004">Selection criteria</h3> <p>We searched for parallel and cross‐over randomised controlled trials in which adults whose asthma was not well controlled by ICS alone were randomly assigned to receive LAMA add‐on or placebo (both combined with ICS) for at least 12 weeks. </p> </section> <section id="CD011397-sec-0005"> <h3 class="title" id="CD011397-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the searches and extracted data from study reports. We used Covidence for duplicate screening, extraction of study characteristics and numerical data and risk of bias ratings. Pre‐specified primary outcomes included exacerbations requiring oral corticosteroids, quality of life and all‐cause serious adverse events. </p> </section> <section id="CD011397-sec-0006"> <h3 class="title" id="CD011397-sec-0006">Main results</h3> <p>We identified five studies that met the inclusion criteria. All studies applied a double‐blind, double‐dummy design, and the population of all studies totalled 2563 adult participants. Study duration ranged from 12 weeks to 52 weeks, and risk of bias across domains in all studies was low. Trials included more women than men (33% to 47% male), and mean age of participants ranged from 41 to 48 years. Participants generally had a long history of asthma, and mean baseline predicted forced expiratory volume in one second (FEV<sub>1</sub>) was between 72% and 75% in three studies reporting pre‐bronchodilator values. </p> <p>The rate of exacerbations requiring oral corticosteroids (OCS) was lower in patients prescribed an LAMA add‐on than in those receiving the same dose of ICS alone (odds ratio (OR) 0.65, 95% confidence interval (CI) 0.46 to 0.93; 2277 participants; four studies; I<sup>2</sup> = 0%; high‐quality evidence), meaning that 27 fewer people per 1000 would have an exacerbation over 21 weeks requiring OCS with LAMA compared with ICS alone (95% CI 42 fewer to 6 fewer). </p> <p>All‐cause serious adverse events (SAEs) and exacerbations requiring hospital admission were rare and the effects too imprecise to permit firm conclusions, but effects suggested that LAMA add‐on may be associated with fewer of both compared with ICS alone (SAEs: OR 0.60, 95% CI 0.23 to 1.57; 2532 participants; four studies; low‐quality evidence; exacerbations requiring hospital admission: OR 0.42, 95% CI 0.12 to 1.47; 2562 participants; five studies; moderate‐quality evidence). Additional therapy with a LAMA showed no clear benefit in terms of quality of life compared with ICS given alone; high‐quality evidence showed only a small mean improvement in quality of life as measured on the Asthma Quality of Life Questionnaire (AQLQ), which was not statistically significant. The same was true for asthma control as measured on the Asthma Control Questionnaire (ACQ), which was based on moderate‐quality evidence. LAMA combined with ICS showed consistent benefit in a range of lung function measures compared with the same dose of ICS alone, and LAMA was not associated with significantly higher rates of adverse events than were reported with placebo. </p> </section> <section id="CD011397-sec-0007"> <h3 class="title" id="CD011397-sec-0007">Authors' conclusions</h3> <p>For adults taking ICS for asthma without a long‐acting beta₂‐agonist (LABA), LAMA given as add‐on treatment reduces the likelihood of exacerbations requiring treatment with OCS and improves lung function. The benefits of LAMA combined with ICS for hospital admissions, all‐cause serious adverse events, quality of life and asthma control remain unknown. </p> <p>Results of this review, along with findings of related reviews conducted to assess the use of LAMA in other clinical scenarios involving asthma, can help to define the role of LAMA in the management of asthma. Trials of longer duration (up to 52 weeks) would provide a better opportunity to observe rare events such as serious adverse events and exacerbations requiring hospital admission. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011397-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011397-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011397-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011397-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011397-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011397-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011397-abs-0004" lang="en"> <h3>Does adding a long‐acting muscarinic antagonist (LAMA) to an inhaled steroid help people with uncontrolled asthma more than an inhaled steroid alone? </h3> <p><b>Main point:</b> People with poorly controlled asthma are less likely to have an asthma attack needing treatment with oral steroids if they take a LAMA on top of their inhaled steroid. LAMA also improve lung function compared with inhaled steroids alone, but their benefit is uncertain for hospital admissions, serious adverse events, quality of life and asthma control. </p> <p><b>Why is this question important?</b> </p> <p>Although lots of medicines are available to treat people with asthma, some patients remain at risk of dying when their disease is poorly controlled. A class of inhaled drugs called long‐acting beta<sub>2</sub>‐agonists (LABA) are usually given as an add‐on to people whose asthma is not well controlled by inhaled steroids alone, and long‐acting muscarinic antagonists (LAMA) are newer drugs now considered as an alternative add‐on for these patients. </p> <p><b>How did we answer the question?</b> </p> <p>We looked for randomised controlled studies of at least 12 weeks that compared LAMA as an add‐on to inhaled steroids versus inhaled steroids alone. Two people searched through databases and websites, looked at all published and unpublished studies, and compiled a list of studies that looked at the review question. The most recent searches were done in April 2015. </p> <p><b>What did we find out?</b> </p> <p>Over five months, fewer people using a LAMA required oral steroids for an asthma attack, and their lung function was improved over that of patients taking inhaled steroids alone. It looked as though people taking LAMA might be less likely to have to go to the hospital for an asthma attack or for another 'serious adverse event', but we couldn't be sure because the studies were short, and these things did not happen very often in either group. A LAMA added to an inhaled steroid did not appear to improve people's quality of life or control of asthma symptoms. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011397-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011397-sec-0095"></div> <h3 class="title" id="CD011397-sec-0096">Implications for practice</h3> <section id="CD011397-sec-0096"> <p>For patients taking ICS without a LABA, LAMA used as add‐on therapy reduces the likelihood of exacerbations requiring treatment with OCS and improves lung function. Benefits of LAMA combined with ICS, including hospital admissions, all‐cause serious adverse events, quality of life and asthma control, have not been ascertained. </p> </section> <h3 class="title" id="CD011397-sec-0097">Implications for research</h3> <section id="CD011397-sec-0097"> <p>Results of this review, along with those of related reviews assessing the use of LAMA in other clinical scenarios of asthma, will help to define the role of LAMA in the management of asthma. This review should be updated as results from ongoing trials are released. Trials of longer duration would provide better opportunities to observe rare events, such as serious adverse events and exacerbations requiring hospital admission. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011397-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011397-sec-0022"></div> <div class="table" id="CD011397-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LAMA add‐on compared with ICS alone for adults with asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>LAMA add‐on compared with ICS alone for adults with asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with asthma not well controlled on ICS alone<br/> <b>Settings:</b> out‐patient<br/> <b>Intervention:</b> LAMA add‐on<br/> <b>Comparison:</b> ICS alone </p> <p><b>Time point:</b> weighted mean duration of the studies included in each analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ICS alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> LAMA add‐on</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring oral corticosteroids (OCS)</b> </p> <p><b>21 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/> (38 to 74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.65</b> <br/> (0.46 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2277<br/> (4 RCTs)† </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LAMA benefit</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (AQLQ)</b> </p> <p>1 = severely impaired;</p> <p>7 = not impaired at all</p> <p><b>23 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean AQLQ score in the control group was 5.44</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean AQLQ score in the intervention group was 0.05 better (0.03 worse to 0.12 better)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1713<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID = 0.5</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause serious adverse events</b> </p> <p><b>24 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (7 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.60</b> <br/> (0.23 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2562<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring hospital admission</b> </p> <p><b>24 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (1 to 9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.42</b> <br/> (0.12 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2562<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lung function ‐ trough FEV<sub>1</sub> (L, change from baseline)</b> </p> <p><b>24 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in trough FEV<sub>1</sub> in the control group was ‐0.02 L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean trough FEV<sub>1</sub> in the intervention group was 0.14 higher (0.10 higher to 0.17 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2459<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma control (ACQ)</b> </p> <p>0 = no impairment;<br/> 6 = maximum impairment </p> <p><b>21 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ACQ total in the control group was 1.47</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ACQ total in the intervention group was 0.08 better (0.19 better to 0.03 worse)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1916<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID = 0.5</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events</b> </p> <p><b>24 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>506 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>493 per 1000<br/> (450 to 539) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.95</b> <br/> (0.80 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2562<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>†Only pooled data from the twin trials were available for this outcome and had to be entered under one study ID.<br/> <b>ACQ:</b> Asthma Control Questionnaire; <b>AEs:</b> adverse events; <b>AQLQ:</b> Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>ICS:</b> inhaled corticosteroid; <b>LAMA:</b> long‐acting muscarinic antagonist; <b>MCID:</b> minimal clinically important difference; <b>OCS:</b> oral corticosteroid. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Confidence interval does not exclude the possibility of benefit from ICS alone, but both confidence limits are well below the established MCID of 0.5 on these scales (no downgrade). </p> <p><sup>b</sup>I<sup>2</sup> = 59%, P value = 0.05 (‐1 inconsistency). </p> <p><sup>c</sup>One study in this analysis allowed participants to continue taking combination ICS/LABA; therefore, some results were derived from participants who do not meet all inclusion criteria for this review. The study accounted for a maximum of 26.7% of the analysis weight, and mostly less than 20% (‐1 indirectness). </p> <p><sup>d</sup>Some statistical heterogeneity but not statistically significant (no downgrade). </p> <p><sup>e</sup>I<sup>2</sup> = 72%, P value = 0.03 (‐1 inconsistency). </p> <p><sup>f</sup>Some studies reported "adverse events (all)" as those not classed as serious; therefore, this figure taken alone may not equal adverse events of all severities. In addition, it was sometimes possible to extract adverse event (AE) data from clinicaltrials.gov only when AEs occurring in &gt; 5% of participants were listed (‐1 indirectness). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011397-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011397-sec-0023"></div> <section id="CD011397-sec-0024"> <h3 class="title" id="CD011397-sec-0024">Description of the condition</h3> <p>Asthma is a "heterogeneous disease, usually characterised by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough that vary over time and in intensity, together with variable expiratory airflow limitation" (<a href="./references#CD011397-bbs2-0043" title="Global Initiative forAsthma . Global Strategy for Asthma Management and Prevention—Revised 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 20 October 2014). [http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf] ">GINA 2014b</a>). Common triggers include allergens, pollutants and viral infections, although endogenous factors have also been identified. The World Health Organization (WHO) recognises the global burden of asthma and estimates a worldwide prevalence of 300 million people of all ages, with 250,000 people dying each year (<a href="./references#CD011397-bbs2-0056" title="World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: A comprehensive approach. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. Geneva, Switzerland: World Health Organization, 2007. ">WHO 2007</a>). Asthma prevalence is greater in urbanised communities, and with the world's urbanised population projected to grow from 45% to 59% by 2025, the number of people diagnosed with asthma is predicted to increase by 100 million over this time (<a href="./references#CD011397-bbs2-0045" title="MasoliM , FabianD , HoltS , BeasleyR . Global Burden of Asthma. http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf (accessed 16 September 2014). ">Global Burden of Asthma Report 2004</a>). Epidemiological data suggest that prevalence is greatest in the developed world, with prevalence amongst adults at 8.2% in the USA (<a href="./references#CD011397-bbs2-0032" title="Centers for Disease Control and Prevention. Asthma Surveillance Data. http://www.cdc.gov/asthma/ (accessed 20 August 2014). ">CDC 2014</a>) and at 9% to 10% in the UK (<a href="./references#CD011397-bbs2-0036" title="Department of Health. An outcomes strategy for COPD and asthma: NHS companion document. https://www.gov.uk/government/publications/an‐outcomes‐strategy‐for‐copd‐and‐asthma‐nhs‐companion‐document (accessed 20 August 2014). ">DOH 2012</a>). Asthma presents a heavy financial burden on health services in the UK and worldwide (<a href="./references#CD011397-bbs2-0044" title="International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. http://www.theunion.org/what‐we‐do/publications/english/global_asthma_report2011.pdf (accessed 4 August 2014). ">Global Asthma Report 2011</a>), with the National Health Service (NHS) spending a billion pounds per year on treatment of patients with asthma (<a href="./references#CD011397-bbs2-0026" title="AsthmaUK . Asthma Facts and FAQs. http://www.asthma.org.uk/asthma‐facts‐and‐statistics (accessed 20 August 2014). ">Asthma UK 2014</a>). This considerable expense represents direct medical costs, such as provision of medicines and frequent general practitioner (GP) consultations, outpatient services and hospital admissions due to poorly controlled disease (<a href="./references#CD011397-bbs2-0027" title="BarnesPJ , JonssonB , KlimJB . The costs of asthma. European Respiratory Journal1996;9:636‐42. [DOI: 10.1183/09031936.96.09040636] ">Barnes 1996</a>). However, the economic cost of asthma is worsened by indirect costs to the patient resulting from time off work or school due to sickness and loss of earnings due to morbidity and early mortality (<a href="./references#CD011397-bbs2-0045" title="MasoliM , FabianD , HoltS , BeasleyR . Global Burden of Asthma. http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf (accessed 16 September 2014). ">Global Burden of Asthma Report 2004</a>). </p> <p>Asthma can present with varying degrees of severity; in the most severe cases, it can cause daily chronic symptoms and frequent exacerbations (defined as acute worsening of asthma symptoms). Overarching principles of treatment focus on controlling daily symptoms and preventing exacerbations. </p> <p>Bronchodilating agents and corticosteroids delivered via inhaler devices are the mainstay in asthma management. Short‐acting bronchodilating agents such as salbutamol are used on a "when required" basis as reliever therapy, and inhaled corticosteroids (ICSs) are given regularly as maintenance therapy. Other agents employed in asthma management include inhaled long‐acting bronchodilating beta<sub>2</sub>‐agonists (LABA) and leukotriene‐receptor antagonists (taken as tablets). Treatment is introduced and is increased through a step‐wise approach, depending on the severity and frequency of symptoms (<a href="./references#CD011397-bbs2-0031" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. https://www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/ (accessed 29 July 2014). ">BTS/SIGN 2012</a>; <a href="./references#CD011397-bbs2-0042" title="Global Initiative forAsthma . Global Strategy for Asthma Management and Prevention 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 28 July 2014). ">GINA 2014a</a>). </p> </section> <section id="CD011397-sec-0025"> <h3 class="title" id="CD011397-sec-0025">Description of the intervention</h3> <p>Asthma treatment is commenced at the level most likely to achieve control of the patient's symptoms; treatment is stepped up to maintain this control and is stepped down when the patient's condition is stable and has been well maintained (<a href="./references#CD011397-bbs2-0031" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. https://www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/ (accessed 29 July 2014). ">BTS/SIGN 2012</a>; <a href="./references#CD011397-bbs2-0042" title="Global Initiative forAsthma . Global Strategy for Asthma Management and Prevention 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 28 July 2014). ">GINA 2014a</a>). Step 1 involves the use of a short‐acting bronchodilating agent alone on a when‐required basis; patients who remain inadequately controlled are increased to step 2, with the introduction of an inhaled corticosteroid (ICS) for regular use as maintenance therapy. Regular daily therapy with an ICS is known to improve lung function and symptom control while reducing airway inflammation and use of reliever therapy compared with intermittent use of an ICS (<a href="./references#CD011397-bbs2-0033" title="ChauhanBF , ChartrandC , DucharmeFM . Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD009611.pub3] ">Chauhan 2013</a>). However, if regular use of an ICS at a low to medium dose does not maintain control of the patient's symptoms—that is, the patient suffers from recurrent exacerbations or nocturnal awakening, or frequently uses reliever therapy to relieve symptoms of breathlessness, chest tightness and wheeze—a step up in treatment to step 3 is required. At step 3 in the management guidelines, the addition of a long‐acting beta<sub>2</sub>‐agonist (LABA) is recommended for adults, as this was found to be superior to alternative treatments (<a href="./references#CD011397-bbs2-0034" title="ChauhanBF , DucharmeFM . Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD003137.pub5] ">Chauhan 2014</a>: <a href="./references#CD011397-bbs2-0037" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2] ">Ducharme 2010</a>). Alternative therapies for people whose asthma is not well controlled on low to medium doses of ICS and for whom a LABA has not worked include introducing a daily leukotriene receptor antagonist tablet or increasing the ICS dose (<a href="./references#CD011397-bbs2-0031" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. https://www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/ (accessed 29 July 2014). ">BTS/SIGN 2012</a>; <a href="./references#CD011397-bbs2-0042" title="Global Initiative forAsthma . Global Strategy for Asthma Management and Prevention 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 28 July 2014). ">GINA 2014a</a>). </p> <p>Long‐acting muscarinic antagonists (LAMAs) are not currently recommended in evidence‐based guidelines for the treatment of patients with asthma; only one LAMA preparation (Spiriva Respimat 2.5 mcg) has had its licence extended for use in people with asthma, and only for patients already taking combination LABA and ICS who have had at least one severe exacerbation in the previous year (<a href="./references#CD011397-bbs2-0040" title="Electronic MedicinesCompendium . License extension 19th September 2014: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/history/20134 (accessed 24 October 2014). ">eMC 2014a</a>). However, several other LAMA preparations are used frequently for the treatment of chronic obstructive pulmonary disease (COPD). COPD, like asthma, is characterised in part by airway obstruction, and patients benefit from the bronchodilating effects of LAMA, which reduce airflow limitation and improve symptoms (<a href="./references#CD011397-bbs2-0050" title="National Institute of Health and Care Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care CG101. http://www.nice.org.uk/guidance/CG101 (accessed 20 August 2014). ">NICE 2010</a>). Previous studies have demonstrated that the LAMA tiotropium significantly reduced the frequency of exacerbations and hospital admissions related to COPD, and improved lung function and quality of life in patients with COPD (<a href="./references#CD011397-bbs2-0048" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3] ">Karner 2014</a>). </p> </section> <section id="CD011397-sec-0026"> <h3 class="title" id="CD011397-sec-0026">How the intervention might work</h3> <p>Long‐acting muscarinic antagonists act by inhibiting the effects of acetylcholine at muscarinic (M)‐receptors. When administered via inhalation, they competitively antagonise M<sub>3</sub>‐receptors, preventing acetylcholine‐mediated constriction of bronchial smooth muscle. This permits dilation of the airways. Their slow dissociation from local M<sub>3</sub>‐receptors and prolonged half‐lives mean that such agents are administered only once or twice daily (<a href="./references#CD011397-bbs2-0038" title="Boehringer IngelheimLimited . Summary of product characteristics: Spiriva 18 microgram inhalation powder, hard capsule. https://www.medicines.org.uk/emc/medicine/10039 (accessed 20 August 2014). ">EMC 2013a</a>; <a href="./references#CD011397-bbs2-0039" title="Boehringer IngelheimLimited . Summary of product characteristics: Spiriva Respimat 2.5 micrograms solution for inhalation. https://www.medicines.org.uk/emc/medicine/20134 (accessed 20 August 2014). ">EMC 2013b</a>; <a href="./references#CD011397-bbs2-0041" title="AlmirallLimited . Sumary of product characteristics: Eklira Genuair 322 micrograms inhalation powder. https://www.medicines.org.uk/emc/medicine/27001 (accessed 20 August 2014). ">EMC 2014b</a>). </p> <p>Chronic obstructive pulmonary disease and asthma share similar symptoms, namely, shortness of breath, chronic cough and wheeze (<a href="./references#CD011397-bbs2-0031" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. https://www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/ (accessed 29 July 2014). ">BTS/SIGN 2012</a>; <a href="./references#CD011397-bbs2-0050" title="National Institute of Health and Care Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care CG101. http://www.nice.org.uk/guidance/CG101 (accessed 20 August 2014). ">NICE 2010</a>). Regulation of airway smooth muscle tone by M‐receptors is enhanced and contributes to airflow obstruction in both COPD and asthma (<a href="./references#CD011397-bbs2-0046" title="GosensR , ZaagsmaJ , MeursH , HalaykoAJ . Muscarinic receptor signalling in the pathophysiology of asthma and COPD. Respiratory Research2006;7(1):73. [DOI: 10.1186/1465‐9921‐7‐73] ">Gosens 2006</a>). Therefore, a reduction in M‐receptor–mediated airway constriction would be beneficial in relieving these common symptoms of COPD and asthma. </p> <p>Previous studies and national guidelines for COPD have shown that LAMA and LABA have comparable efficacy in treating patients with moderate COPD (<a href="./references#CD011397-bbs2-0050" title="National Institute of Health and Care Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care CG101. http://www.nice.org.uk/guidance/CG101 (accessed 20 August 2014). ">NICE 2010</a>). LABA is also a bronchodilator and is the favoured treatment for introduction at step 3 or 4 of asthma management, when it is administered concomitantly with an ICS to improve control of symptoms (<a href="./references#CD011397-bbs2-0042" title="Global Initiative forAsthma . Global Strategy for Asthma Management and Prevention 2014. http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf (accessed 28 July 2014). ">GINA 2014a</a>). Although a LAMA mediates bronchial smooth muscle relaxation in a manner different from that of a LABA, its bronchodilatory effect may be beneficial for patients who require a step up in their asthma management when ICS alone is insufficient. </p> </section> <section id="CD011397-sec-0027"> <h3 class="title" id="CD011397-sec-0027">Why it is important to do this review</h3> <p>Although several evidence‐based therapies and non‐pharmacological strategies are available to improve control of symptoms and to prevent exacerbations of asthma, mortality due to asthma remains a risk for patients. Asthma UK reported 1167 deaths due to asthma in 2011, while "75% of hospital admissions for asthma are avoidable and as many as 90% of the deaths from asthma are preventable" (<a href="./references#CD011397-bbs2-0026" title="AsthmaUK . Asthma Facts and FAQs. http://www.asthma.org.uk/asthma‐facts‐and‐statistics (accessed 20 August 2014). ">Asthma UK 2014</a>). This highlights the fact that current management of asthma remains suboptimal and indicates that development of new management strategies and treatments would be beneficial. </p> <p>As a result of the common features of COPD and asthma—such as up‐regulation of M‐receptor–mediated airway tone and subsequent symptoms of breathlessness, cough and wheeze—known benefits of inhaled LAMA in COPD may also be beneficial for patients with asthma, particularly those with severe asthma whose condition remains inadequately controlled by current recommended step 3 therapy. </p> <p>Previous trials have demonstrated the potentially beneficial effects of the LAMA tiotropium on lung function in patients with asthma (<a href="./references#CD011397-bbs2-0051" title="PetersS , KunselmanS , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363:1715‐26. [DOI: 10.1056/NEJMoa1008770] ">Peters 2010</a>; <a href="./references#CD011397-bbs2-0025" title="VogelbergC , EngelM , Moroni‐ZentgrafP , Leonaviciute‐KlimantavicieneM , SigmundR , DownieJ , et al. Once‐daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose‐ranging study [Abstract]. Clinical and Translational Allergy2014;4(Suppl 1):2 [O5]. ">Vogelberg 2014</a>). However, a definitive conclusion on the benefit of LAMA in asthma is lacking, as is information explaining where in the current step‐wise management strategy they would be most beneficial. Therefore, a systematic review of all available randomised controlled trials on the addition of a LAMA to an ICS would be beneficial in revealing any benefit to be derived from the use of LAMA in asthma that remains uncontrolled by an ICS alone. </p> <p>Three associated reviews will assess the following.</p> <p> <ul id="CD011397-list-0001"> <li> <p>LAMA add‐on compared with LABA add‐on.</p> </li> <li> <p>LAMA add‐on compared with increased ICS dose.</p> </li> <li> <p>LAMA add‐on as triple therapy with LABA + ICS compared with LABA + ICS alone.</p> </li> </ul> </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011397-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011397-sec-0028"></div> <p>To assess the efficacy and safety of a long‐acting muscarinic antagonist (LAMA) added to any dose of an inhaled corticosteroid (ICS) compared with the same dose of ICS alone for adults whose asthma is not well controlled. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011397-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011397-sec-0029"></div> <section id="CD011397-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011397-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included parallel and cross‐over randomised controlled trials (RCTs) of at least 12 weeks' duration reported as full text, those published as abstract only and those with unpublished data. </p> <p>We did not exclude studies on the basis of blinding.</p> </section> <section id="CD011397-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included adults (aged 18 years or older) whose asthma was not well controlled by ICS alone. We excluded trials that included participants with chronic respiratory co‐morbidities (e.g. COPD, bronchiectasis). </p> <p>If studies included adults and adolescents or children younger than 12 years and data are not reported separately, we included them if the mean age in both groups was over 18 years. </p> </section> <section id="CD011397-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing a LAMA added to any dose of ICS therapy versus continued use of ICS at the same dose. This meant that studies in which participants were randomly assigned to LAMA or placebo, with inclusion criteria specifying that participants should be taking a stable dose of background ICS, were included. We included studies that permitted the use of short‐acting medications (e.g. salbutamol, terbutaline, ipratropium) as reliever therapy. We excluded trials in which a LABA was given as part of the randomly assigned treatment and those in which most participants continued their LABA alongside the randomly assigned treatment. Studies involving the addition of any of the following LAMA preparations were included. </p> <p> <ul id="CD011397-list-0002"> <li> <p>Tiotropium (Spiriva Handihaler or Respimat).</p> </li> <li> <p>Aclidinium bromide (Eklira Genuair).</p> </li> <li> <p>Glycopyrronium bromide (Seebri Breezhaler).</p> </li> </ul> </p> </section> <section id="CD011397-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD011397-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011397-list-0003"> <li> <p>Exacerbations requiring oral corticosteroids.</p> </li> <li> <p>Quality of life (measured on a validated asthma scale, e.g. Asthma Quality of Life Questionnaire). </p> </li> <li> <p>All‐cause serious adverse events.</p> </li> </ul> </p> </section> <section id="CD011397-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011397-list-0004"> <li> <p>Exacerbations requiring hospitalisation.</p> </li> <li> <p>Lung function (in particular, trough forced expiratory volume in one second (FEV<sub>1</sub>)). </p> </li> <li> <p>Asthma control (as measured on a validated scale, e.g. Asthma Control Questionnaire, Asthma Control Test). </p> </li> <li> <p>Any adverse events.</p> </li> </ul> </p> <p>Reporting by trial authors of one or more of the outcomes listed here was not an inclusion criterion for the review. </p> <p>If exacerbations were reported as a composite of more than one definition (e.g. study participants with one or more exacerbations requiring hospitalisation or an emergency department (ED) visit), we analysed these separately. </p> </section> </section> </section> <section id="CD011397-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011397-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Trials Search Co‐ordinator for the Group. This Register contains trial reports identified through systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED) and PsycINFO, and by handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD011397-sec-0101">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy provided in <a href="./appendices#CD011397-sec-0107">Appendix 2</a>. </p> <p>We also conducted a search of ClinicalTrials.gov (www.ClinicalTrials.gov) and the World Health Organization (WHO) trials portal (www.who.int/ictrp/en/). We searched all databases from their inception to the present, and we imposed no restriction on language of publication. </p> </section> <section id="CD011397-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles to look for additional references. We searched relevant manufacturers' websites for trials and other information. </p> <p>We searched for errata or retractions from included studies published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed) on 9 April 2015. </p> </section> </section> <section id="CD011397-sec-0040"> <h3 class="title" id="CD011397-sec-0040">Data collection and analysis</h3> <section id="CD011397-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Using <a href="./references#CD011397-bbs2-0035" title="The Alfred Hospital, Monash University, National ICT Australia and the University of London. Covidence. Prahran VIC: Alfred Health, 2013. ">Covidence</a>, two review authors (DA and KK) independently screened titles and abstracts for inclusion of all potential studies identified as a result of the search. We retrieved the full‐text study reports/publications; two review authors (DA and KK) independently screened the full‐text reports to identify studies for inclusion, and identified and recorded reasons for exclusion of ineligible studies. We will resolve disagreements through discussion or, if required, by consultation with a third person. We identified and excluded duplicates and collated multiple reports on the same study, so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) flow diagram and a <a href="./references#CD011397-sec-0116" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD011397-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form in Covidence that had been piloted on at least one study in the review to document study characteristics and outcome data. Both review authors (DA and KK) extracted the following study characteristics from included studies. </p> <p> <ul id="CD011397-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study settings, withdrawals and dates of study. </p> </li> <li> <p>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: interventions, comparisons, concomitant medications and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected and time points reported.</p> </li> <li> <p>Notes: funding for trial and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (DA and KK) independently extracted outcome data from included studies. We noted in the <a href="./references#CD011397-sec-0115" title="">Characteristics of included studies</a> table if outcome data were not reported in a useable way, and we resolved disagreements by discussion. One review author (KK) transferred data into the Review Manager (<a href="./references#CD011397-bbs2-0052" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014 (RevMan)</a>) file. We double‐checked that data had been entered correctly by comparing data presented in the systematic review versus those provided in study reports. </p> </section> <section id="CD011397-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (DA and KK) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011397-bbs2-0047" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved disagreements by discussion and assessed risk of bias according to the following domains. </p> <p> <ul id="CD011397-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in the <a href="#CD011397-sec-0063">Risk of bias in included studies</a> table. We summarised risk of bias judgements across different studies for each of the domains listed and considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different than for a patient‐reported pain scale). When information on risk of bias was related to unpublished data or correspondence with a trial author, we noted this in the <a href="#CD011397-sec-0063">Risk of bias in included studies</a> table. </p> <p>In cases for which the method of random sequence generation or allocation concealment was not adequately described, but the study was funded by a manufacturer with whom methods had previously been confirmed, we assumed that the same methods were applied. In the event of such insufficient reporting, we contacted the study author or sponsor to ask for additional information to clarify uncertainties and to support our assumption that the same methods were applied. </p> <p>When considering treatment effects, we took into account the risk of bias for studies that contributed to that outcome. </p> <section id="CD011397-sec-0044"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to this published protocol and reported deviations from it in the <a href="#CD011397-sec-0113">Differences between protocol and review</a> section of the systematic review. </p> </section> </section> <section id="CD011397-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios, and continuous data as mean differences or standardised mean differences. We entered presented data as a scale with a consistent direction of effect. We narratively described skewed data reported as medians and interquartile ranges. When both raw data and adjusted analyses (e.g. accounting for baseline differences) were presented, we used the latter. When data published in peer‐reviewed papers was different from those given on clinicaltrials.gov, we cross‐checked them (using generic inverse vairience (GIV) and RevMan analyses when only mean difference vs placebo was available), and we contacted study sponsor or trial authors to ask for more information if we noted discrepancies in effects. </p> <p>We undertook meta‐analyses only when this was meaningful (i.e. when treatments, participants and the underlying clinical question were similar enough for pooling to make sense). </p> <p>When multiple trial arms were reported in a single trial, we included only the relevant arms. When two comparisons (e.g. drug A vs placebo and drug B vs placebo) were combined in the same meta‐analysis, we halved the control group to avoid double counting. </p> <p>When both change from baseline and endpoint scores were available for continuous data, we used change from baseline unless most studies reported endpoint scores. If a study reported outcomes at multiple time points, we used the end‐of‐study measurement. </p> <p>When both an analysis using only participants who completed the trial and an analysis that imputed data for participants who were randomly assigned but did not provide endpoint data (e.g. last observation carried forward) were available, we used the latter. </p> <p>For dichotomous outcomes, we assumed equivalence of treatments if the odds ratio estimate and its 95% confidence interval were between the pre‐defined arbitrary limits of 0.9 and 1.1. </p> </section> <section id="CD011397-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we used participants rather than events as the unit of analysis (i.e. number of adults admitted to hospital rather than number of admissions per adult). </p> </section> <section id="CD011397-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was identified as an abstract only). When this was not possible, and when missing data were thought to introduce serious bias, we performed a sensitivity analysis to explore the impact of including such studies in the overall assessment of results<b>. </b> </p> </section> <section id="CD011397-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity (e.g. I<sup>2</sup> &gt; 30%), we reported this and explored possible causes through pre‐specified subgroup analyses.  </p> </section> <section id="CD011397-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>We were not able to pool more than 10 trials, so we could not examine a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD011397-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model for all analyses, as we expected variation in effects due to differences in study populations and methods. We performed sensitivity analyses using fixed‐effect models. </p> <section id="CD011397-sec-0051"> <h5 class="title">'Summary of findings' table</h5> <p>We created <a href="./full#CD011397-tbl-0001">summary of findings Table for the main comparison</a> to document all primary and secondary outcomes listed in the protocol<i>.</i> We used the five GRADE (Grades of Recommendation, Assessment, Development and Evaluation) considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to studies that contributed data to the meta‐analyses for pre‐specified outcomes. We applied methods and recommendations as described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011397-bbs2-0047" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) using GRADEpro software (<a href="./references#CD011397-bbs2-0030" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. GRADE Working Group, 2008. ">Brozek 2008</a>). We justified all decisions to downgrade or upgrade the quality of studies by using footnotes and by making comments when necessary to aid the reader's understanding of the review. </p> </section> </section> <section id="CD011397-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses for primary outcomes.</p> <p> <ul id="CD011397-list-0007"> <li> <p>Duration of therapy (≤ 6 months, &gt; 6 months).</p> </li> <li> <p>Corticosteroid dose (according to <a href="http://archie.cochrane.org/sections/documents/view?document=z1405201158356969485713945219635%26format=REVMAN#REF-GINA-2014" target="_blank">GINA 2014</a>, defined as low, medium and high cutoffs). </p> </li> <li> <p>Dose and type of LAMA (e.g. tiotropium HandiHaler 18 mcg, tiotropium Respimat 5 mcg).</p> </li> </ul> </p> <p>We used the formal test for subgroup interactions provided in <a href="./references#CD011397-bbs2-0052" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014 (RevMan)</a>. </p> </section> <section id="CD011397-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We planned the following sensitivity analyses on primary outcomes, with the following studies excluded. </p> <p> <ul id="CD011397-list-0008"> <li> <p>Unpublished data.</p> </li> <li> <p>Studies at high risk of bias for blinding (participants and personnel).</p> </li> </ul> </p> <p>We conducted an unplanned sensitivity analysis on primary outcomes by removing one study in which around half of the participants were taking a LABA, which was outside the inclusion criteria. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011397-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011397-sec-0054"></div> <section id="CD011397-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD011397-sec-0056"> <h4 class="title">Results of the search</h4> <p>We identified 71 records through electronic database searches and obtained a further 122 records from additional resources (clinicaltrials.gov, reference lists of other publications and drug company trial registries). Of the total 193, we identified 54 as duplicates and screened the remaining 139. Upon screening titles and abstracts, we excluded 105 that did not meet the inclusion criteria. We excluded 22 of the remaining 34 records after retrieving and inspecting full texts; these related to 20 studies. The main reasons for exclusion were as follows: LABA were part of the randomly assigned treatment (n = 6), the study was too short (n = 6) and the wrong comparator was used (n = 5). The remaining 12 records related to five studies that met all inclusion criteria and were included in the qualitative synthesis. All five studies reported data that could be included in at least one meta‐analysis. Trial flow is shown in <a href="#CD011397-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011397-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011397-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011397-sec-0057"> <h4 class="title">Included studies</h4> <section id="CD011397-sec-0058"> <h5 class="title">Design and duration</h5> <p>We identified five studies that made the comparison of interest and met the inclusion criteria. Details of study characteristics are provided in <a href="./references#CD011397-sec-0115" title="">Characteristics of included studies</a> and in <a href="#CD011397-tbl-0002">Table 1</a>. All studies were of a double‐blind, double‐dummy design, and the population for all studies totalled 2563 adult participants. Duration of studies ranged from 12 weeks to 52 weeks. Only the LAMA plus ICS and placebo (ICS‐only) groups in each study are relevant to the present review and are considered herein. The LABA plus ICS groups featured in <a href="./references#CD011397-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. DahlR , BatemanED , CasaleT , PizzichiniE , VandewalkerM , VirchowJC , et al. Once‐daily tiotropium Respimat as add‐on to at least medium‐ to high‐dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen. 2014:515. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. http://www.clinicaltrials.gov/show/NCT00350207 (accessed 19 December 2014). ">NCT00350207</a>, <a href="./references#CD011397-bbs2-0003" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB5. KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled, parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172821 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014). ">NCT01172821</a> and <a href="./references#CD011397-bbs2-0002" title="KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled,parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172808 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014). ">NCT01172808</a> are considered in a related systematic review (see <a href="./references#CD011397-bbs2-0049" title="KewKM , EvansDJW , AndersonDE , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2] ">Kew 2015</a>). When further clarification of study design or outcome analyses was required, we contacted study authors, who were able to provide additional information and analyses. </p> <div class="table" id="CD011397-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomly assigned groups</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (mean, y)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% pred FEV<sub>1</sub> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. DahlR , BatemanED , CasaleT , PizzichiniE , VandewalkerM , VirchowJC , et al. Once‐daily tiotropium Respimat as add‐on to at least medium‐ to high‐dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen. 2014:515. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. http://www.clinicaltrials.gov/show/NCT00350207 (accessed 19 December 2014). ">NCT00350207</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 5 mcg daily</p> <p>2) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5</p> <p>44.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.1</p> <p>75.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0002" title="KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled,parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172808 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014). ">NCT01172808</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 2.5 mcg daily</p> <p>2) Tiotropium Respimat 5 mcg daily</p> <p>3) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> <p>44.4</p> <p>42.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.1</p> <p>72.2</p> <p>73.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0003" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB5. KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled, parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172821 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014). ">NCT01172821</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 2.5 mcg daily</p> <p>2) Tiotropium Respimat 5 mcg daily</p> <p>3) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.0</p> <p>44.3</p> <p>43.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.5</p> <p>72.2</p> <p>73.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0004" title="NCT01316380 . A phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) compared to placebo over 12 weeks in mild persistent asthma. http://www.clinicaltrials.gov/show/NCT01316380 (accessed 19 December 2014). PaggiaroP , EngelM , TudoricN , ForstnerB , RadeczkyE , ZubekV , et al. Phase III trial of tiotropium as add‐on therapy to low‐dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]. European Respiratory Journal2013;42(Suppl 57):877s [P4133]. PaggiaroP , HalpinDMG , BuhlR , EngelM , ZubekV , BlahovaZ , et al. Tiotropium Respimat add‐on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB4. ">NCT01316380</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 2.5 mcg daily</p> <p>2) Tiotropium Respimat 5 mcg daily</p> <p>3) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.8</p> <p>41.9</p> <p>42.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.3*</p> <p>93.2</p> <p>91.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 2.5 mcg daily</p> <p>2) Tiotropium Respimat 5 mcg daily</p> <p>3) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.7</p> <p>42.6</p> <p>47.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> <p>N/R</p> <p>N/R</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Total N is the number randomly assigned to the groups of interest for this review. Age and % predicted FEV<sub>1</sub> are presented as mean values. </p> <p>DB = double‐blind; DD = double‐dummy; NR = not reported; OL = open label.</p> <p>* Values here are post‐bronchodilator.</p> </div> </div> </section> <section id="CD011397-sec-0059"> <h5 class="title">Participant inclusion and exclusion criteria</h5> <p>Included participants were between 18 and 75 years of age at the start of the study and had a three‐month history of asthma, which was first diagnosed before the age of 40. Included participants were symptomatic despite their current maintenance therapy, which they had been using for at least four weeks before the trials began. Participants included in the studies were able to correctly use all inhaler devices randomly assigned to them and were able to carry out all tests and procedures related to collating outcome measures. </p> <p>Patients with a concomitant "significant disease" were excluded from the study. This was defined by Boehringer Ingelheim as a "disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial; patients with a clinically relevant abnormal screening (visit 1) haematology or blood chemistry if the abnormality defines a significant disease as defined in exclusion criterion no. 1". Patients with very unstable asthma and requiring in excess of 10 puffs of reliever therapy per day on two consecutive days during the screening period were also excluded from the trials, as were those with concomitant lung disease, arrhythmia or recent history of heart failure or acute coronary disease (within the previous 12 months and 6 months, respectively). Smokers and ex‐smokers who had stopped smoking the year before the trial commenced were also excluded from the studies. </p> </section> <section id="CD011397-sec-0060"> <h5 class="title">Participant baseline characteristics</h5> <p>The mean age of participants and the proportion of males and females in each study group were reported in all five included studies. The mean ages of participants were between 41 and 48 years. The percentage of male participants remained consistently less than half of the study population and ranged from 33.3% to 46.8%. </p> <p>The mean percentage predicted FEV<sub>1</sub> at baseline was between 72% and 75% in three studies reporting pre‐bronchodilator values, and 91% and 94% across groups in the only study reporting post‐bronchodilator values (<a href="./references#CD011397-bbs2-0004" title="NCT01316380 . A phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) compared to placebo over 12 weeks in mild persistent asthma. http://www.clinicaltrials.gov/show/NCT01316380 (accessed 19 December 2014). PaggiaroP , EngelM , TudoricN , ForstnerB , RadeczkyE , ZubekV , et al. Phase III trial of tiotropium as add‐on therapy to low‐dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]. European Respiratory Journal2013;42(Suppl 57):877s [P4133]. PaggiaroP , HalpinDMG , BuhlR , EngelM , ZubekV , BlahovaZ , et al. Tiotropium Respimat add‐on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB4. ">NCT01316380</a>). Participants had a long history of asthma, and the mean number of years since diagnosis ranged from 16 to 23 across groups in the four studies reporting this measure. </p> </section> <section id="CD011397-sec-0061"> <h5 class="title">Characteristics of the interventions</h5> <p>All of the studies included in this review compared the use of tiotropium in addition to the pre‐study ICS medication versus the use of pre‐study ICS medication alone. All studies included tiotropium at a dose of 5 mcg daily, and four of the five studies were multi‐arm trials that included separate arms receiving 2.5 mcg (low‐dose) and 5 mcg (high‐dose) of tiotropium daily (<a href="./references#CD011397-bbs2-0002" title="KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled,parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172808 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014). ">NCT01172808</a>; <a href="./references#CD011397-bbs2-0003" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB5. KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled, parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172821 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014). ">NCT01172821</a>; <a href="./references#CD011397-bbs2-0004" title="NCT01316380 . A phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) compared to placebo over 12 weeks in mild persistent asthma. http://www.clinicaltrials.gov/show/NCT01316380 (accessed 19 December 2014). PaggiaroP , EngelM , TudoricN , ForstnerB , RadeczkyE , ZubekV , et al. Phase III trial of tiotropium as add‐on therapy to low‐dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]. European Respiratory Journal2013;42(Suppl 57):877s [P4133]. PaggiaroP , HalpinDMG , BuhlR , EngelM , ZubekV , BlahovaZ , et al. Tiotropium Respimat add‐on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB4. ">NCT01316380</a>; <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>). All studies delivered tiotropium via a Respimat inhaler. Matching placebo Respimat inhalers were provided to participants randomly assigned to the placebo group. </p> <p>Inhaled corticosteroids were not included as part of the randomly assigned treatment but were specified as part of the inclusion criteria of all studies. Inclusion criteria for <a href="./references#CD011397-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. DahlR , BatemanED , CasaleT , PizzichiniE , VandewalkerM , VirchowJC , et al. Once‐daily tiotropium Respimat as add‐on to at least medium‐ to high‐dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen. 2014:515. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. http://www.clinicaltrials.gov/show/NCT00350207 (accessed 19 December 2014). ">NCT00350207</a> included treatment with 400 to 1000 mcg of budesonide or equivalent. One study included only participants with at least a four‐week history of treatment with a low, stable dose of ICS (<a href="./references#CD011397-bbs2-0004" title="NCT01316380 . A phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) compared to placebo over 12 weeks in mild persistent asthma. http://www.clinicaltrials.gov/show/NCT01316380 (accessed 19 December 2014). PaggiaroP , EngelM , TudoricN , ForstnerB , RadeczkyE , ZubekV , et al. Phase III trial of tiotropium as add‐on therapy to low‐dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]. European Respiratory Journal2013;42(Suppl 57):877s [P4133]. PaggiaroP , HalpinDMG , BuhlR , EngelM , ZubekV , BlahovaZ , et al. Tiotropium Respimat add‐on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB4. ">NCT01316380</a>). Remaining studies required at least a four‐week history of treatment with a medium, stable dose of ICS (<a href="./references#CD011397-bbs2-0002" title="KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled,parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172808 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014). ">NCT01172808</a>; <a href="./references#CD011397-bbs2-0003" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB5. KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled, parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172821 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014). ">NCT01172821</a>; <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>). However, in <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>, participants were included if they took ICS alone <i>or</i> in fixed combination with a LABA. We included this study because participants were not required to be taking the ICS/LABA combination to be included in the trial, and the split between those taking ICS alone (43%) and those given ICS alongside a LABA (57%) was relatively even. Sensitivity analyses were performed to remove this study from the primary outcomes. Participants in all studies continued this usual maintenance dose of ICS throughout the study period, including those taking LABA alongside ICS in fixed combination in <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>. The actual ICS taken by participants per day was not available in most studies. All studies permitted the use of rescue beta‐agonist medication during the study period. </p> </section> </section> <section id="CD011397-sec-0062"> <h4 class="title">Excluded studies</h4> <p>After viewing full texts, we excluded 13 studies. The main reasons for exclusion included use of a LABA as part of the randomly assigned treatment and the requirement that participants take ICS/LABA combination therapy if they were to be included in the trial (n = 4 records, relevant to a separate review (<a href="./references#CD011397-bbs2-0049" title="KewKM , EvansDJW , AndersonDE , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2] ">Kew 2015</a>)). Four records were excluded because they used a comparator not relevant to this review. Other reasons for exclusion were these: study duration too short (i.e. duration &lt; 12 weeks; n = 3 records), wrong intervention used (n = 1 record) and wrong population examined (n = 1 record). Excluded studies and reasons for exclusion are listed in <a href="./references#CD011397-sec-0116" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011397-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, included studies showed high methodological quality and were largely given low risk of bias ratings (<a href="#CD011397-fig-0002">Figure 2</a>). When insufficient information was available in published and publicly available isources, we contacted the trial authors to ask for clarification of methods used. </p> <div class="figure" id="CD011397-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011397-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011397-sec-0064"> <h4 class="title">Allocation</h4> <p>Information within the clinicaltrials.gov records or published reports was generally insufficient to warrant low risk of bias ratings, but prior contact with study sponsors and additional contact for this review confirmed that standard practices were applied by study sponsors (who used computerised codes and automated allocation systems). For this reason, we judged all included studies to be at low risk of selection bias. </p> </section> <section id="CD011397-sec-0065"> <h4 class="title">Blinding</h4> <p>We rated all studies as having low risk of bias for blinding of participants, personnel and outcome assessors. All studies were designed to be double‐blind and double‐dummy, with the use of matching placebo inhalers. </p> </section> <section id="CD011397-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>We rated all studies as having low risk of bias due to attrition. Participant dropout was less than 10% in all groups within the included studies. Investigators reported he numbers of participants who were randomly assigned to a study arm but did not complete the study, as well as the numbers of participants who provided data for all outcome measures. They also provided reasons for non‐completion of the study. </p> </section> <section id="CD011397-sec-0067"> <h4 class="title">Selective reporting</h4> <p>We originally rated two of the included studies as having high risk of bias for selective reporting (<a href="./references#CD011397-bbs2-0002" title="KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled,parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172808 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014). ">NCT01172808</a>, <a href="./references#CD011397-bbs2-0003" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB5. KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled, parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172821 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014). ">NCT01172821</a>) because the number of participants in each group who had an exacerbation of asthma was not given, even though this was listed as a secondary outcome measure. It was suggested that this was done because “less than 50% of participants in each treatment group experienced an asthma exacerbation”. Also in relation to "all adverse events" reported by these two studies, researchers reported only adverse events experienced by at least 5% of the study population, which led to an apparent underestimation of the magnitude of all adverse events experienced. Both of these issues were resolved when the full text was published in a peer‐reviewed journal, so we assessed all studies as having low risk of bias for selective reporting. </p> </section> <section id="CD011397-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We deemed one study to have unclear risk of bias due to another potential source. This involved an imbalance in the number of participants in each study arm who had never smoked and was considered to present potential risk for study outcomes. We noted no issues with the other four studies and consequently rated them as having low risk of bias. </p> </section> </section> <section id="CD011397-sec-0069"> <h3 class="title" id="CD011397-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD011397-tbl-0001"><b>Summary of findings for the main comparison</b> LAMA add‐on compared with ICS alone for adults with asthma</a> </p> <section id="CD011397-sec-0070"> <h4 class="title">Primary outcomes</h4> <section id="CD011397-sec-0071"> <h5 class="title">Exacerbations requiring oral corticosteroids</h5> <p>LAMA reduced the odds that participants would need to take oral corticosteroids (OCS) for an exacerbation of asthma compared with those for ICS alone (odds ratio (OR) 0.65, 95% confidence interval (CI) 0.46 to 0.93; participants = 2277; four studies; I<sup>2</sup> = 0%). As shown in <a href="#CD011397-fig-0003">Figure 3</a>, this means that 27 fewer people per 1000 would require an OCS for an exacerbation longer than 21 weeks if they took a LAMA rather than an ICS alone (95% CI 42 fewer to 6 fewer). Data for the twin trials (<a href="./references#CD011397-bbs2-0002" title="KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled,parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172808 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014). ">NCT01172808</a> and <a href="./references#CD011397-bbs2-0003" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB5. KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled, parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172821 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014). ">NCT01172821</a>) were available only as a pooled result, so they had to be entered as one study. We rated the evidence as high quality. </p> <div class="figure" id="CD011397-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Cates plot showing the absolute effect for the primary outcome.In the control group (ICS alone), 80 out of 1000 people had exacerbations requiring oral corticosteroids over 21 weeks, compared with 53 out of 1000 people for the intervention group (95% CI 38 to 74)(LAMA add‐on). As such, in this time period, 27 fewer people taking LAMA add‐on would have had an exacerbation requiring oral corticosteroids than if they continued taking ICS alone." data-id="CD011397-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Cates plot showing the absolute effect for the primary outcome.</p> <p>In the control group (ICS alone), 80 out of 1000 people had exacerbations requiring oral corticosteroids over 21 weeks, compared with 53 out of 1000 people for the intervention group (95% CI 38 to 74)(LAMA add‐on). As such, in this time period, 27 fewer people taking LAMA add‐on would have had an exacerbation requiring oral corticosteroids than if they continued taking ICS alone. </p> </div> </div> </div> <p>As a supplementary post hoc analysis, we looked at events coded as 'asthma' in the non‐serious adverse events tables using MedDRA (Medical Dictionary for Regulatory Activities) terminology.. The sort of asthma events that would have been counted under this term is not clear, so findings are difficult to interpret, but all studies reported data in this way. Fewer 'adverse events classified as asthma' were reported for groups taking LAMA than for those who did not, although the confidence interval showed no difference (OR 0.85, 95% CI 0.69 to 1.05; participants = 2561; five studies; I<sup>2</sup> = 0%). Risk of bias assessments and unpublished data sensitivity analyses were not necessary, but we performed a sensitivity analysis after removing <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a> ‐ the study in which some participants continued to take a long‐acting beta<sub>2</sub>‐agonist ‐ and found that results were largely similar (OR 0.87, 95% CI 0.70 to 1.10; participants 2276; four studies; I<sup>2</sup> = 0%). We graded the quality of evidence for this analysis as low after downgrading, because only a small population contributed data to this analysis, only two of the five included studies measured this outcome and poor definitions were provided for exacerbations requiring OCS in each of these studies. </p> </section> <section id="CD011397-sec-0072"> <h5 class="title">Quality of life</h5> <p>Scores on the Asthma Quality of Life Questionnaire (AQLQ) were slightly higher for those taking a LAMA than for those continuing on ICS alone, but confidence intervals showed benefit for both treatments and were not within the range of the scale's established minimal clinically important difference (MCID) of 0.5 (MD 0.05, 95% CI ‐0.03 to 0.12; participants = 1713; three studies; I<sup>2</sup> = 0%). None of the planned sensitivity analyses could be performed on this outcome (no studies at high risk of bias, no unpublished data and no outcomes reported by the partial ICS/LABA study (<a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>)). We graded evidence for this outcome as high in quality. </p> </section> <section id="CD011397-sec-0073"> <h5 class="title">All‐cause serious adverse events</h5> <p>People in these studies who were taking LAMA reported fewer serious adverse events, but the pooled effect was too inconsistent and imprecise to suggest a definitive benefit over ICS alone (OR 0.60, 95% CI 0.23 to 1.57; participants = 2562; five studies; I<sup>2</sup> = 59%). Given the heterogeneity, we performed a sensitivity analysis using a fixed‐effect model, which increased the precision of the estimate, suggesting fewer serious adverse events in people taking LAMA add‐on. As with exacerbations requiring OCS, we performed a sensitivity analysis after removing <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>; the magnitude of the effect was reduced, as was heterogeneity, but it remained similarly imprecise (OR 0.87, 95% CI 0.37 to 2.05; participants = 2277; five studies; I<sup>2</sup> = 27%). This outcome was downgraded to low quality as the result of heterogeneity and inclusion in <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a> of some participants taking a LABA. </p> </section> </section> <section id="CD011397-sec-0074"> <h4 class="title">Secondary outcomes</h4> <section id="CD011397-sec-0075"> <h5 class="title">Exacerbations requiring hospitalisation</h5> <p>A total of nine people required hospital admission for an asthma exacerbation during study periods, which meant that the estimate was imprecise because few events were reported (OR 0.42, 95% CI 0.12 to 1.47; participants = 2562; five studies; I<sup>2</sup> = 0%). The effect included no benefit due to this imprecision but fewer hospital admissions with LAMA add‐on. We also downgraded this outcome because some participants in <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a> did not meet the inclusion criteria. </p> </section> <section id="CD011397-sec-0076"> <h5 class="title">Lung function</h5> <section id="CD011397-sec-0077"> <h6 class="title">Forced expiratory volume in one second (FEV<sub>1</sub>) </h6> <p>Trough FEV<sub>1</sub> measurements improved by an additional 140 mL in people taking LAMA add‐on compared with those given ICS alone (mean difference (MD) 0.14 mL, 95% CI 0.10 to 0.17; participants = 2459; five studies; I<sup>2</sup> = 26%). People who had been taking LAMA add‐on also had much improved peak FEV<sub>1</sub> measurements (MD 0.19 L, 95% CI 0.15 to 0.23; participants = 1923; three studies; I<sup>2</sup> = 39%). Both analyses showed a degree of inconsistency between study results, but this finding was not statistically significant. We rated the evidence for this outcome as high in quality. </p> </section> <section id="CD011397-sec-0078"> <h6 class="title">Peak expiratory flow (PEF)</h6> <p>Trough measurement of PEF was almost 30 L/min better in people taking LAMA add‐on (MD 28.07 L/min, 95% CI 22.51 to 33.64; participants = 2456; five studies; I<sup>2</sup> = 24%), and again some heterogeneity between study results was evident. </p> </section> <section id="CD011397-sec-0079"> <h6 class="title">Forced vital capacity (FVC)</h6> <p>People taking a LAMA showed trough FVC improvements 90 mL greater than those found in people not taking a LAMA (MD 0.09, 95% CI 0.05 to 0.13; participants = 2002; four studies; I<sup>2</sup> = 8%), and the result for peak measurements was of similar magnitude and precision (MD 0.11, 95% CI 0.08 to 0.15; participants = 1922; three studies; I<sup>2</sup> = 6%). Both analyses revealed a small amount of statistical heterogeneity. </p> </section> </section> <section id="CD011397-sec-0080"> <h5 class="title">Asthma control</h5> <p>Participants taking LAMA add‐on improved slightly more on the Asthma Control Questionnaire (ACQ) than those taking ICS alone, but confidence intervals for the effect showed no difference and heterogeneity was significant (MD ‐0.08, 95% CI ‐0.19 to 0.03; participants = 1916; three studies; I<sup>2</sup> = 72%). Results and confidence intervals also fall well below the scale's MCID of 0.5. We downgraded to moderate the quality of the evidence used to assess differences in ACQ scores because results were inconsistent. The same studies and one other reported the number of people who improved by at least the MCID (ACQ 'responders'). Using this dichotomy, people in the LAMA group were more likely to 'respond' than those taking continued ICS, but the confidence intervals did not rule out the possibility that ICS alone was better, and significant variation between studies was noted (OR 1.23, 95% CI 0.87 to 1.74; participants = 2009; three studies; I<sup>2</sup> = 69%). </p> </section> <section id="CD011397-sec-0081"> <h5 class="title">Any adverse events</h5> <p>People taking LAMA add‐on did not have a significantly different number of adverse events of any kind compared with those given ICS alone (OR 0.95, 95% CI 0.80 to 1.14; participants = 2562; five studies; I<sup>2</sup> = 0%). This outcome was graded as low in quality because some participants were taking LABA in <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>, and because some studies reported only adverse events that occurred in at least 5% of participants. </p> </section> </section> <section id="CD011397-sec-0082"> <h4 class="title">Subgroup analyses</h4> <section id="CD011397-sec-0083"> <h5 class="title">Duration of therapy</h5> <p>All of the studies reporting exacerbations requiring OCS and the three studies reporting quality of life on the AQLQ were less than six months in duration, so it was not possible to perform a subgroup analysis by duration for these two primary outcomes. These outcomes also showed no important statistical heterogeneity, so it was not necessary to investigate effect modifiers. </p> <p>A subgroup analysis by study duration for the remaining primary outcome ‐ all‐cause serious adverse events ‐ showed a significant difference between the pooled result for the four shorter trials and the one‐year‐long trial (I<sup>2</sup> = 80%; P value = 0.03). This must be interpreted with caution because of the observational nature of subgroup analyses, and because only one trial was included in one of the subgroups. </p> </section> <section id="CD011397-sec-0084"> <h5 class="title">Corticosteroid dose</h5> <p>No statistical heterogeneity was noted between studies reporting exacerbations requiring OCS, so comparisons in a steroid dose subgroup analysis were meaningless. The three studies reporting quality of life on the AQLQ used medium doses of inhaled steroids, so no comparison could be made. </p> <p>We split studies reporting the remaining primary outcome ‐ all‐cause serious adverse events ‐ into low‐dose (<a href="./references#CD011397-bbs2-0004" title="NCT01316380 . A phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) compared to placebo over 12 weeks in mild persistent asthma. http://www.clinicaltrials.gov/show/NCT01316380 (accessed 19 December 2014). PaggiaroP , EngelM , TudoricN , ForstnerB , RadeczkyE , ZubekV , et al. Phase III trial of tiotropium as add‐on therapy to low‐dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]. European Respiratory Journal2013;42(Suppl 57):877s [P4133]. PaggiaroP , HalpinDMG , BuhlR , EngelM , ZubekV , BlahovaZ , et al. Tiotropium Respimat add‐on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB4. ">NCT01316380</a>) and medium‐dose (<a href="./references#CD011397-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. DahlR , BatemanED , CasaleT , PizzichiniE , VandewalkerM , VirchowJC , et al. Once‐daily tiotropium Respimat as add‐on to at least medium‐ to high‐dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen. 2014:515. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. http://www.clinicaltrials.gov/show/NCT00350207 (accessed 19 December 2014). ">NCT00350207</a>; <a href="./references#CD011397-bbs2-0002" title="KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled,parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172808 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014). ">NCT01172808</a>; <a href="./references#CD011397-bbs2-0003" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB5. KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled, parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172821 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014). ">NCT01172821</a>; <a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>) subgroups. <a href="./references#CD011397-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. DahlR , BatemanED , CasaleT , PizzichiniE , VandewalkerM , VirchowJC , et al. Once‐daily tiotropium Respimat as add‐on to at least medium‐ to high‐dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen. 2014:515. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. http://www.clinicaltrials.gov/show/NCT00350207 (accessed 19 December 2014). ">NCT00350207</a> allowed doses up to 1000 mcg budesonide equivalent (high dose), but these were classified as medium dose, as more of the range fell under the medium dose category (400 to 800 mcg). Heterogeneity within the outcome was not accounted for by differences in ICS dose (heterogeneity within the medium‐dose subgroup remained significant). </p> </section> <section id="CD011397-sec-0085"> <h5 class="title">Dose and type of LAMA</h5> <p>All included studies used tiotropium Respimat as their LAMA, and all but one study included two dose groups that were merged in the main comparison. To compare these, we separated out the dose groups and compared them against the same control group, while adjusting for double counting in each analysis. Tests for subgroup differences did not suggest differences between the two doses for any of the primary outcomes (<a href="./references#CD011397-fig-0018" title="">Analysis 2.2</a>). </p> <p>In addition to the planned subgroup analysis, we performed a direct comparison of the two doses using the four studies in which this was possible (all but <a href="./references#CD011397-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. DahlR , BatemanED , CasaleT , PizzichiniE , VandewalkerM , VirchowJC , et al. Once‐daily tiotropium Respimat as add‐on to at least medium‐ to high‐dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen. 2014:515. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. http://www.clinicaltrials.gov/show/NCT00350207 (accessed 19 December 2014). ">NCT00350207</a>). The effect estimate was too imprecise for review authors to conclude whether one dose was better than another for reducing exacerbations requiring OCS (<a href="./references#CD011397-fig-0022" title="">Analysis 3.1</a>). Direct dose comparisons for quality of life on the AQLQ (<a href="./references#CD011397-fig-0023" title="">Analysis 3.2</a>) and for all‐cause serious adverse events (<a href="./references#CD011397-fig-0024" title="">Analysis 3.3</a>) did not suggest differences in effect for the two doses. </p> </section> </section> <section id="CD011397-sec-0086"> <h4 class="title">Sensitivity analyses</h4> <section id="CD011397-sec-0087"> <h5 class="title">Studies at high risk of bias for blinding of participants and personnel</h5> <p>We rated none of the studies as having high risk of bias for blinding.</p> </section> <section id="CD011397-sec-0088"> <h5 class="title">Unpublished data (i.e. no peer‐reviewed full paper available)</h5> <p>No conference abstracts were included, and all data included in the primary outcomes were available in peer‐reviewed reports or on publicly available websites. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011397-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011397-sec-0089"></div> <section id="CD011397-sec-0090"> <h3 class="title" id="CD011397-sec-0090">Summary of main results</h3> <p>Five studies met the inclusion criteria; all were double‐blind, double‐dummy randomised controlled trials and ranged in length from 12 to 52 weeks. We included in this review data from 2563 participants; we conducted this review to compare the use of inhaled corticosteroid (ICS) only versus tiotropium (LAMA) 2.5 mcg or 5 mcg daily in addition to ICS therapy. Participants in all included studies continued their pre‐study maintenance dose of ICS throughout the study period, which ranged from low dose to high dose. More women than men were included in the trials (33% to 47% male), and mean age of participants ranged from 41 to 48 years. Participants generally had a long history of asthma, and mean baseline percentage predicted FEV<sub>1</sub> was between 72% and 75% in three studies reporting pre‐bronchodilator values. All studies reported good methods and were considered to be at low risk of bias for most of the assessed domains (<a href="#CD011397-fig-0002">Figure 2</a>). </p> <p>High‐quality evidence shows that the rate of exacerbations requiring oral corticosteroids (OCS) was significantly lower in patients prescribed a LAMA add‐on (27 fewer per 1000 participants, 95% CI 6 fewer to 42 fewer) than in those receiving the same dose of ICS alone. </p> <p>Similarly, four fewer people per 1000 participants would have an exacerbation resulting in hospitalisation if prescribed a LAMA add‐on compared with the same dose of ICS alone; this result was not statistically significant, with a confidence interval ranging from five fewer to three more people (per 1000) having such an exacerbation. Eleven fewer people (per 1000) would experience a serious adverse event when receiving a LAMA add‐on; however, the confidence interval ranged from 22 fewer people to 16 more people experiencing a serious adverse event with the addition of LAMA therapy and highlighted the imprecision of this result. Such events were relatively rare among the study population; this may have been exacerbated by the short study period described in four of the five included studies (&lt; six months). </p> <p>The addition of LAMA therapy did not show clear benefit for quality of life compared with ICS alone; high‐quality evidence of only a small mean increase in quality of life score (AQLQ) was not statistically significant. The same was true for asthma control as measured on the ACQ, which was based on evidence of moderate quality. </p> <p>Addition of a LAMA led to significant improvement in lung function compared with the same dose of ICS alone, with FEV<sub>1</sub> increased by 0.14 L. Evidence used to evaluate this outcome was graded as high, despite slight heterogeneity and inclusion of data from only one study, which also recruited patients who were using a stable maintenance dose of LABA with ICS and permitted its use throughout the study period. LAMA was not associated with significantly higher rates of adverse events than were reported with placebo. </p> </section> <section id="CD011397-sec-0091"> <h3 class="title" id="CD011397-sec-0091">Overall completeness and applicability of evidence</h3> <p>The evidence base included in this review was lacking in several aspects. All included studies used tiotropium at a dose of 5 mcg daily (licensed dose) or 2.5 mcg daily; therefore, we cannot determine whether the results of this study apply to all other LAMA agents, such as glycopyrronium or aclidinium bromide, which, although not currently indicated for asthma, may be used to treat patients with asthma in the future. Included studies were designed to compare LAMA versus placebo, both combined with the usual ICS dose, but did not detail which ICS participants had used. Therefore, we cannot determine if the results of this study are affected by ICS choice. Study populations included participants using low, medium and high doses of ICS. Therefore, we cannot disregard the fact that this variation in ICS dose may have contributed to observed analyses, although the proportions of particpants using low, medium and high doses of ICS were consistent in both study arms. </p> <p>All studies included in this review were industry‐sponsored trials that were conducted to a very high standard and in a controlled manner. However, this scenario may not truly reflect normal practice, for example, in relation to patient concordance with therapy, which may vary widely in general practice. </p> <p>This study analysed the effects of LAMA add‐on therapy on the frequency of all‐cause serious adverse events and exacerbations resulting in hospital admission. Such events were relatively rare in the study populations, and no significant reduction in the frequency of these outcome measures was found. This may reflect inclusion only of patients at step 2 of asthma management (<a href="./references#CD011397-bbs2-0031" title="British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. https://www.brit‐thoracic.org.uk/guidelines‐and‐quality‐standards/ (accessed 29 July 2014). ">BTS/SIGN 2012</a>), whose disease was not so severe that exacerbations often resulted in hospital admission; however, the low frequency of such events may have been exacerbated by the relatively short duration of the included studies. The benefit of LAMA add‐on in reducing all‐cause serious adverse events was more pronounced in the only included study lasting longer than six months; therefore, future studies assessing these outcome measures in a similar population would benefit from longer trial duration for more accurate assessment of the effects of LAMA add‐on therapy. </p> <p>Use of LAMA in the management of asthma is relatively new, with only one UK license extension granted for Spiriva Respimat. The licensed indication is only for use as triple therapy for patients already receiving maintenance therapy with a LABA and 800 mcg of budesonide or equivalent, who have had a least one severe exacerbation in the previous year. This group of patients is different from those considered in this review, but the study of LAMA in patients with less severe asthma suggests that further license extensions may be forthcoming. We hope that future versions of this review will provide more powerful and applicable findings on the use of LAMA for patients with less severe asthma. </p> </section> <section id="CD011397-sec-0092"> <h3 class="title" id="CD011397-sec-0092">Quality of the evidence</h3> <p>We rated evidence for one of the primary outcome measures ‐ exacerbations requiring treatment with OCS ‐ as high in quality. Although we included only 137 events in the analysis, we did not consider the effect imprecise, and we included data for more than 2200 people from four multi‐centre studies. We rated asthma‐related quality of life on the AQLQ as high. </p> <p>We downgraded evidence for all‐cause serious adverse events to low quality as the result of inconsistency and indirectness, the latter because the study (<a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a>) included participants using an ICS, as well as those using an ICS/LABA in a fixed combination, and did not present results separately for these two groups of patients. Thus, results from participants who did not meet the inclusion criteria for this review have been included and reduce the reliability of the results. This is also true for exacerbations resulting in hospitalisation, lung function and all adverse events. </p> <p>We downgraded the evidence for asthma control (ACQ total) to moderate because of significant inconsistency. </p> <p>We downgraded the quality of the analysis of all adverse events to low, in part because of indirectness of the trial, which included some participants taking LABA/ICS, and because some of the included trials were available only on clinicaltrials.gov, which lists only adverse events experienced by a minimum of 5% of the study population. </p> </section> <section id="CD011397-sec-0093"> <h3 class="title" id="CD011397-sec-0093">Potential biases in the review process</h3> <p>We conducted this review in accordance with the standards set by MECIR 2013 and in keeping with the protocol (<a href="./references#CD011397-bbs2-0057" title="AllisonDE , KewKM , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS for adults with asthma. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011397] ">Allison 2014</a>). We have reported deviations from the protocol in the section titled <a href="#CD011397-sec-0113">Differences between protocol and review</a>. </p> <p>We conducted an additional sensitivity analysis to exclude one trial, which included participants taking a LABA in addition to a stable ICS dose before and during the study period. </p> <p>As definitions for reported adverse events related to asthma were lacking in these studies, along with details on whether such exacerbations required oral corticosteroids, we conducted an analysis of all adverse events due to asthma. </p> <p>A skilled information specialist conducted the main electronic searches; thus it is unlikely that any relevant, qualifying studies or trials have been overlooked for inclusion in this review. We supplemented the main searches with searches of other sources (pharmaceutical company clinical trial registries and reference lists of associated studies and reviews), in addition to those required by MECIR 2013 (i.e. clinicaltrials.gov, World Health Organization (WHO) trials portal). We attempted to contact the authors of any trials from which were we required additional data or clarification of methods. </p> </section> <section id="CD011397-sec-0094"> <h3 class="title" id="CD011397-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>Use of LAMA in the management of asthma has been reviewed in many studies. Timmer et al. found that tiotropium, at doses of 5 mcg daily or 2.5 mcg twice daily, resulted in significant improvement in all measures of lung function compared with placebo, when added to medium‐dose ICS for patients with asthma, with a significant increase in adverse events (<a href="./references#CD011397-bbs2-0055" title="TimmerW , Moroni‐ZentgrafP , CornelissenP , UnseldA , PizzichiniE , BuhlR . Once‐daily tiotropium Respimat® 5 μg is an efficacious 24‐h bronchodilator in adults with symptomatic asthma. Respiratory Medicine2014:[Epub ahead of print]. [DOI: 10.1016/j.rmed.2014.12.005] ">Timmer 2014</a>). This is consistent with the findings of other studies (<a href="./references#CD011397-bbs2-0028" title="BeehK , Moroni‐ZentgrafP , AblingerO , HollaenderovaZ , UnseldA , EngelM , et al. Tiotropium Respimat® in asthma: a double‐blind, randomised, dose‐ranging study in adult patients with moderate asthma. Respiratory Research2014;15:61. [DOI: 10.1186/1465‐9921‐15‐61] ">Beeh 2014</a>) and systematic reviews, some of which also highlighted the benefit of LAMA added on to other standard asthma treatments, such as ICS/LABA combination therapy, when the disease is inadequately controlled (<a href="./references#CD011397-bbs2-0029" title="BefekaduE , OnofreiC , ColiceG . Tiotropium in asthma: a systematic review. Journal of Asthma and Allergy2014;7:11‐21. [DOI: 10.2147/JAA.S38841] ">Befekadu 2014</a>; <a href="./references#CD011397-bbs2-0053" title="RodrigoGJ , Castro‐RodriguezJA . What is the role of tiotropium in asthma?: a systematic review with meta‐analysis. Chest2015;147(2):388‐96. [DOI: 10.1378/chest.14‐1698] ">Rodrigo 2015</a>; <a href="./references#CD011397-bbs2-0054" title="TianJW , ChenJW , ChenR , ChenX . Tiotropium versus placebo for inadequately controlled asthma: a meta‐analysis. Respiratory Care2014;59(5):654‐66. [DOI: 10.4187/respcare.02703] ">Tian 2014</a>). Rodrigo et al. identified that tiotropium add‐on to ICS not only significantly improved lung function but also significantly reduced the rate of exacerbations and improved asthma control (<a href="./references#CD011397-bbs2-0053" title="RodrigoGJ , Castro‐RodriguezJA . What is the role of tiotropium in asthma?: a systematic review with meta‐analysis. Chest2015;147(2):388‐96. [DOI: 10.1378/chest.14‐1698] ">Rodrigo 2015</a>). </p> <p>One study comparing the efficacy of tiotropium versus a LABA found that tiotropium at a dose of 18 mcg daily was comparable with salmeterol at a dose of 50 mcg twice daily when added to medium‐dose ICS (<a href="./references#CD011397-bbs2-0051" title="PetersS , KunselmanS , IcitovicN , MooreWC , PascualR , AmeredesBT , et al. Tiotropium bromide step‐up therapy for adults with uncontrolled asthma. New England Journal of Medicine2010;363:1715‐26. [DOI: 10.1056/NEJMoa1008770] ">Peters 2010</a>). This is consistent with findings of other systematic reviews and a related Cochrane review undertaken to assess the same hypothesis (<a href="./references#CD011397-bbs2-0049" title="KewKM , EvansDJW , AndersonDE , BoyterAC . Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011438.pub2] ">Kew 2015</a>; <a href="./references#CD011397-bbs2-0053" title="RodrigoGJ , Castro‐RodriguezJA . What is the role of tiotropium in asthma?: a systematic review with meta‐analysis. Chest2015;147(2):388‐96. [DOI: 10.1378/chest.14‐1698] ">Rodrigo 2015</a>). </p> <p>This evidence supports the use of tiotropium as a bronchodilator in the management of asthma; however, further research is needed to determine the efficacy of other LAMA drugs, and oflong‐term treatment, as most available evidence has been provided by studies four to 14 weeks in duration. The results of this review are not consistent with the evidence because these studies were only four weeks in duration, and data may reflect only temporary, short‐term improvement in symptoms associated with LAMA use; all studies included in this review have a minimum duration of 12 weeks, and results may highlight the fact that these short‐term improvements in disease state are not maintained. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011397-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011397-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011397-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Cates plot showing the absolute effect for the primary outcome.In the control group (ICS alone), 80 out of 1000 people had exacerbations requiring oral corticosteroids over 21 weeks, compared with 53 out of 1000 people for the intervention group (95% CI 38 to 74)(LAMA add‐on). As such, in this time period, 27 fewer people taking LAMA add‐on would have had an exacerbation requiring oral corticosteroids than if they continued taking ICS alone." data-id="CD011397-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Cates plot showing the absolute effect for the primary outcome.</p> <p>In the control group (ICS alone), 80 out of 1000 people had exacerbations requiring oral corticosteroids over 21 weeks, compared with 53 out of 1000 people for the intervention group (95% CI 38 to 74)(LAMA add‐on). As such, in this time period, 27 fewer people taking LAMA add‐on would have had an exacerbation requiring oral corticosteroids than if they continued taking ICS alone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 1 Exacerbations requiring oral corticosteroids." data-id="CD011397-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 1 Exacerbations requiring oral corticosteroids.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 2 Quality of life (AQLQ)." data-id="CD011397-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 2 Quality of life (AQLQ).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 3 All‐cause serious adverse events." data-id="CD011397-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 3 All‐cause serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 4 Exacerbations requiring hospital admission." data-id="CD011397-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 4 Exacerbations requiring hospital admission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 5 Trough FEV1 (litres, change from baseline)." data-id="CD011397-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 5 Trough FEV<sub>1</sub> (litres, change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 6 Peak FEV1 (litres, change from baseline)." data-id="CD011397-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 6 Peak FEV<sub>1</sub> (litres, change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 7 Trough PEF (litres/min, change from baseline)." data-id="CD011397-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 7 Trough PEF (litres/min, change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 8 Trough FVC (litres, change from baseline)." data-id="CD011397-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 8 Trough FVC (litres, change from baseline).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 9 Peak FVC (litres, change from baseline)." data-id="CD011397-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 9 Peak FVC (litres, change from baseline).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 10 Asthma control (ACQ)." data-id="CD011397-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 10 Asthma control (ACQ).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 11 Asthma control (ACQ 'responder')." data-id="CD011397-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 11 Asthma control (ACQ 'responder').</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 12 Any adverse events." data-id="CD011397-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 12 Any adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 LAMA add‐on vs ICS alone, Outcome 13 Adverse events classified as asthma." data-id="CD011397-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 LAMA add‐on vs ICS alone, Outcome 13 Adverse events classified as asthma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 1 All‐cause serious adverse events ‐ by study duration." data-id="CD011397-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 1 All‐cause serious adverse events ‐ by study duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 2 Exacerbations requiring oral corticosteroids ‐ by Respimat dose." data-id="CD011397-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 2 Exacerbations requiring oral corticosteroids ‐ by Respimat dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 3 Quality of life (AQLQ) ‐ by Respimat dose." data-id="CD011397-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 3 Quality of life (AQLQ) ‐ by Respimat dose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 4 All‐cause serious adverse events ‐ by Respimat dose." data-id="CD011397-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 4 All‐cause serious adverse events ‐ by Respimat dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses, Outcome 5 All‐cause serious adverse events ‐ by ICS dose." data-id="CD011397-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses, Outcome 5 All‐cause serious adverse events ‐ by ICS dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Respimat 2.5 mcg vs 5 mcg, Outcome 1 Exacerbations requiring oral corticosteroids." data-id="CD011397-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Respimat 2.5 mcg vs 5 mcg, Outcome 1 Exacerbations requiring oral corticosteroids.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Respimat 2.5 mcg vs 5 mcg, Outcome 2 Quality of life (AQLQ)." data-id="CD011397-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Respimat 2.5 mcg vs 5 mcg, Outcome 2 Quality of life (AQLQ).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011397-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/urn:x-wiley:14651858:media:CD011397:CD011397-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_t/tCD011397-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Respimat 2.5 mcg vs 5 mcg, Outcome 3 All‐cause serious adverse events." data-id="CD011397-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Respimat 2.5 mcg vs 5 mcg, Outcome 3 All‐cause serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/media/CDSR/CD011397/image_n/nCD011397-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011397-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LAMA add‐on compared with ICS alone for adults with asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>LAMA add‐on compared with ICS alone for adults with asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with asthma not well controlled on ICS alone<br/> <b>Settings:</b> out‐patient<br/> <b>Intervention:</b> LAMA add‐on<br/> <b>Comparison:</b> ICS alone </p> <p><b>Time point:</b> weighted mean duration of the studies included in each analysis </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ICS alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> LAMA add‐on</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring oral corticosteroids (OCS)</b> </p> <p><b>21 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/> (38 to 74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.65</b> <br/> (0.46 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2277<br/> (4 RCTs)† </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LAMA benefit</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life (AQLQ)</b> </p> <p>1 = severely impaired;</p> <p>7 = not impaired at all</p> <p><b>23 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean AQLQ score in the control group was 5.44</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean AQLQ score in the intervention group was 0.05 better (0.03 worse to 0.12 better)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1713<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID = 0.5</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause serious adverse events</b> </p> <p><b>24 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (7 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.60</b> <br/> (0.23 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2562<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring hospital admission</b> </p> <p><b>24 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (1 to 9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.42</b> <br/> (0.12 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2562<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lung function ‐ trough FEV<sub>1</sub> (L, change from baseline)</b> </p> <p><b>24 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in trough FEV<sub>1</sub> in the control group was ‐0.02 L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean trough FEV<sub>1</sub> in the intervention group was 0.14 higher (0.10 higher to 0.17 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2459<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma control (ACQ)</b> </p> <p>0 = no impairment;<br/> 6 = maximum impairment </p> <p><b>21 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ACQ total in the control group was 1.47</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ACQ total in the intervention group was 0.08 better (0.19 better to 0.03 worse)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1916<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MCID = 0.5</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events</b> </p> <p><b>24 weeks</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>506 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>493 per 1000<br/> (450 to 539) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.95</b> <br/> (0.80 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2562<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>†Only pooled data from the twin trials were available for this outcome and had to be entered under one study ID.<br/> <b>ACQ:</b> Asthma Control Questionnaire; <b>AEs:</b> adverse events; <b>AQLQ:</b> Asthma Quality of Life Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>ICS:</b> inhaled corticosteroid; <b>LAMA:</b> long‐acting muscarinic antagonist; <b>MCID:</b> minimal clinically important difference; <b>OCS:</b> oral corticosteroid. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Confidence interval does not exclude the possibility of benefit from ICS alone, but both confidence limits are well below the established MCID of 0.5 on these scales (no downgrade). </p> <p><sup>b</sup>I<sup>2</sup> = 59%, P value = 0.05 (‐1 inconsistency). </p> <p><sup>c</sup>One study in this analysis allowed participants to continue taking combination ICS/LABA; therefore, some results were derived from participants who do not meet all inclusion criteria for this review. The study accounted for a maximum of 26.7% of the analysis weight, and mostly less than 20% (‐1 indirectness). </p> <p><sup>d</sup>Some statistical heterogeneity but not statistically significant (no downgrade). </p> <p><sup>e</sup>I<sup>2</sup> = 72%, P value = 0.03 (‐1 inconsistency). </p> <p><sup>f</sup>Some studies reported "adverse events (all)" as those not classed as serious; therefore, this figure taken alone may not equal adverse events of all severities. In addition, it was sometimes possible to extract adverse event (AE) data from clinicaltrials.gov only when AEs occurring in &gt; 5% of participants were listed (‐1 indirectness). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">LAMA add‐on compared with ICS alone for adults with asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011397-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomly assigned groups</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (mean, y)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% pred FEV<sub>1</sub> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0001" title="BatemanED , KornmannO , SchmidtP , PivovarovaA , EngelM , FabbriLM . Tiotropium is non inferior to salmeterol in maintaining improved lung function in B16‐Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology2011;128(2):315‐22. DahlR , BatemanED , CasaleT , PizzichiniE , VandewalkerM , VirchowJC , et al. Once‐daily tiotropium Respimat as add‐on to at least medium‐ to high‐dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status. 33rd Congress of the European Academy of Allergy and Clinical Immunology, Copenhagen. 2014:515. NCT00350207 . A 16‐week randomised, placebo‐controlled, double‐blind, double‐dummy, parallel‐group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat inhaler (2 actuations of 2.5 mcg once daily) with that of salmeterol from the hydrofluoroalkane metered dose inhaler (2 actuations of 25 mcg twice daily) in moderate persistent asthma patients with the B16‐Arg/Arg genotype. http://www.clinicaltrials.gov/show/NCT00350207 (accessed 19 December 2014). ">NCT00350207</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 5 mcg daily</p> <p>2) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5</p> <p>44.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.1</p> <p>75.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0002" title="KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled,parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172808 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172808 (accessed 19 December 2014). ">NCT01172808</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 2.5 mcg daily</p> <p>2) Tiotropium Respimat 5 mcg daily</p> <p>3) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.7</p> <p>44.4</p> <p>42.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.1</p> <p>72.2</p> <p>73.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0003" title="CasaleT , BleeckerE , MeltzerE , PizzichiniE , SchmidtO , BatemanE , et al. Phase III trials to investigate tiotropium as add‐on therapy to inhaled corticosteroids for patients with symptomatic asthma: trial design and planned statistical analyses. Allergy2013;68:377. CasaleTB , BatemanED , DahlR , PizzichiniE , VandewalkerML , VirchowJC , et al. Tiotropium Respimat add‐on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of Th2 inflammatory status. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB5. KerstjensHAM , CasaleTB , BleeckerER , MeltzerEO , PizzichiniE , SchmidtO , et al. Tiotropium or salmeterol as add‐on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double‐blind, placebo‐controlled, parallel‐group, active‐comparator, randomised trials. Lancet Respiratory Medicine 2015 Feb 12 [Epub ahead of print]. NCT01172821 . A Phase III Randomised, Double‐blind, Placebo‐controlled, Parallel‐group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 mcg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 mcg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma. http://www.clinicaltrials.gov/show/NCT01172821 (accessed 19 December 2014). ">NCT01172821</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 2.5 mcg daily</p> <p>2) Tiotropium Respimat 5 mcg daily</p> <p>3) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.0</p> <p>44.3</p> <p>43.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.5</p> <p>72.2</p> <p>73.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0004" title="NCT01316380 . A phase III, randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) compared to placebo over 12 weeks in mild persistent asthma. http://www.clinicaltrials.gov/show/NCT01316380 (accessed 19 December 2014). PaggiaroP , EngelM , TudoricN , ForstnerB , RadeczkyE , ZubekV , et al. Phase III trial of tiotropium as add‐on therapy to low‐dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: design and planned analyses [Abstract]. European Respiratory Journal2013;42(Suppl 57):877s [P4133]. PaggiaroP , HalpinDMG , BuhlR , EngelM , ZubekV , BlahovaZ , et al. Tiotropium Respimat add‐on to inhaled corticosteroids improves lung function in patients with symptomatic mild asthma: results from a phase III trial. Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB4. ">NCT01316380</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 2.5 mcg daily</p> <p>2) Tiotropium Respimat 5 mcg daily</p> <p>3) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.8</p> <p>41.9</p> <p>42.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.3*</p> <p>93.2</p> <p>91.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011397-bbs2-0005" title="NCT01340209 . A phase III randomised, double‐blind, placebo‐controlled, parallel‐group trial to evaluate safety and efficacy of tiotropium inhalation solution delivered via Respimat inhaler (2.5 and 5 µg once daily) compared with placebo over 52 weeks in patients with moderate to severe persistent asthma. http://www.clinicaltrials.gov/show/NCT01340209 (accessed 19 December 2014). OhtaK , IchinoseM , TohdaY , EngelM , Moroni‐ZentgrafP , KunimitsuS , et al. Long‐term once daily tiotropium Respimat is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo‐controlled study. PLoS ONE2015;10(4):e0124109. ">NCT01340209</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DB, DD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1) Tiotropium Respimat 2.5 mcg daily</p> <p>2) Tiotropium Respimat 5 mcg daily</p> <p>3) Placebo (ICS alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.7</p> <p>42.6</p> <p>47.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/R</p> <p>N/R</p> <p>N/R</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Total N is the number randomly assigned to the groups of interest for this review. Age and % predicted FEV<sub>1</sub> are presented as mean values. </p> <p>DB = double‐blind; DD = double‐dummy; NR = not reported; OL = open label.</p> <p>* Values here are post‐bronchodilator.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/full#CD011397-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011397-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LAMA add‐on vs ICS alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations requiring oral corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.46, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life (AQLQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.03, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.23, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Exacerbations requiring hospital admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.12, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Trough FEV<sub>1</sub> (litres, change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.10, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Peak FEV<sub>1</sub> (litres, change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.15, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Trough PEF (litres/min, change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.07 [22.51, 33.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Trough FVC (litres, change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.05, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Peak FVC (litres, change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.08, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Asthma control (ACQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.19, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Asthma control (ACQ 'responder') <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.87, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.80, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events classified as asthma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.69, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LAMA add‐on vs ICS alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011397-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause serious adverse events ‐ by study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.23, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ≤ 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.37, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 &gt; 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.07, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Exacerbations requiring oral corticosteroids ‐ by Respimat dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.46, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Respimat 2.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.29, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Respimat 5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.48, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life (AQLQ) ‐ by Respimat dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.03, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Respimat 2.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.08, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Respimat 5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.05, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause serious adverse events ‐ by Respimat dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.30, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Respimat 2.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.22, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Respimat 5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.21, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause serious adverse events ‐ by ICS dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.35, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low‐dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.03, 8.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Medium‐dose ICS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011397-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Respimat 2.5 mcg vs 5 mcg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations requiring oral corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.29, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life (AQLQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.09, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.50, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Respimat 2.5 mcg vs 5 mcg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011397.pub2/references#CD011397-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011397.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011397-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011397-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011397-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011397-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011397\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011397\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011397\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011397\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011397\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011397.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011397.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011397.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011397.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011397.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728755886"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011397.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728755890"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011397.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecc39ac81f56f',t:'MTc0MDcyODc1Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 